Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
MindMed (NASDAQ: MNMD) granted an inducement option to a newly hired non-executive employee on October 14, 2025. The option covers 28,000 common shares, with an exercise price equal to MindMed's closing share price on the grant date.
The option vests over four years: 25% at the first anniversary and the remaining 75% in substantially equal monthly increments over the next three years, subject to continued employment. The grant was approved by the Compensation Committee on October 7, 2025 and was issued outside MindMed's equity incentive plans as a material inducement under NASDAQ Rule 5635(c)(4).
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has issued inducement grants to three new non-executive employees. The grants consist of options to purchase 182,800 common shares with grant dates of September 15 and September 22, 2025.
The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly increments over the following three years. The exercise price is set at the closing price of MindMed's shares on the respective grant dates. These grants were approved by MindMed's Compensation Committee on September 10, 2025, in compliance with NASDAQ Rule 5635(c)(4).
MindMed (NASDAQ: MNMD) presented significant findings from a cross-sectional retrospective study at Psych Congress 2025, analyzing over 75,000 respondents from the 2022 National Health and Wellness Survey. The study revealed alarming statistics about suicidal ideation (SI) in individuals with Generalized Anxiety Disorder (GAD).
Key findings include: 48% of severe GAD patients reported almost daily SI, 78% with moderate GAD and 91% with severe GAD reported SI within two weeks. The study also found that 65% of GAD patients reported major depressive disorder (MDD) symptoms. Among the general population, 28.4% of U.S. adults reported SI, with highest rates among men (33%), young adults aged 18-34 (47.5%), Hispanic individuals (47.6%), and students (42.9%).
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced new employee inducement grants. The company issued options to five newly hired non-executive employees to purchase a total of 78,750 common shares.
The options were granted between August 25 and September 8, 2025, with exercise prices matching MindMed's closing share price on each respective grant date. The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.
MindMed (NASDAQ: MNMD) has published groundbreaking Phase 2b clinical trial results in JAMA for MM120 (LSD) in treating Generalized Anxiety Disorder (GAD). The study, involving 198 adults with moderate-to-severe GAD, tested four dose levels (25, 50, 100, or 200 µg) without psychotherapy.
The 100 µg dose showed optimal results, achieving a 7.6-point greater reduction in HAM-A scores versus placebo at Week 4, with 65% clinical response and 48% remission rates sustained through Week 12. The treatment was well-tolerated, with most adverse effects being mild-to-moderate and transient.
Based on these results, the FDA has granted Breakthrough Therapy Designation to MM120 for GAD. MindMed is currently conducting three Phase 3 trials, with topline data expected in 2026.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in four major investor conferences in September 2025. The company will engage in fireside chat presentations at the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 9), Baird Global Healthcare Conference (Sept 10), and TD Cowen's Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Sept 18).
The presentations will be available via webcast on MindMed's Investor Relations website, with replays accessible for up to 90 days after each event.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced new employee inducement grants. The company issued 425,450 stock options and 34,500 performance share units (PSUs) to five newly hired non-executive employees.
The stock options will vest over four years, with 25% vesting in the first year and the remaining 75% vesting monthly over three years. The PSUs will vest on the third anniversary of the grant date, with potential earnings ranging from 0% to 200% based on performance metrics. These grants were approved by MindMed's Compensation Committee and issued under NASDAQ Rule 5635(c)(4).
MindMed (NASDAQ: MNMD) reported Q2 2025 financial results and business updates, highlighting strong progress in its clinical trials. The company is advancing three pivotal Phase 3 trials of MM120 ODT for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD), with data expected in 2026. Cash position stands at $237.9 million, sufficient to fund operations into 2027.
Key financial metrics include R&D expenses of $29.8 million (up from $14.6M YoY) and a net loss of $42.7 million (compared to $5.9M in Q2 2024). The company strengthened its leadership team by appointing Brandi L. Roberts as CFO and continues to show strong enrollment across all clinical trials, with Phase 3 Voyage trial data anticipated in 1H 2026, followed by Panorama and Emerge trials in 2H 2026.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has scheduled its Q2 2025 financial results webcast for July 31, 2025, at 4:30 p.m. EDT. The company will present its financial performance for the quarter ended June 30, 2025, along with recent business updates.
The presentation will include a Q&A session for analysts, and participants are advised to join 15 minutes before the start time. A replay will be available on MindMed's investor relations website for at least 30 days following the event.
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has granted stock options to six new non-executive employees. The inducement grants total 96,400 common shares with grant dates of July 7 and July 14, 2025.
The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. The exercise price is set at the closing price of MindMed shares on the respective grant dates. These grants were approved by MindMed's Compensation Committee on June 26, 2025, in compliance with NASDAQ Rule 5635(c)(4).
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
